OncoMatch/Clinical Trials/NCT05147844
Toripalimab Combined With Radiotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma
Is NCT05147844 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Toripalimab for nasopharyngeal carcinoma.
Treatment: Toripalimab — The aim of the study was to determine the efficacy and safety of toripalimab combined with radiotherapy in the treatment of oligometastatic nasopharyngeal carcinoma
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Disease stage
Required: Stage IVB
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Exception: unsuitable or unwilling to receive chemotherapy according to the judgment of investigator
Unsuitable or unwilling to receive chemotherapy according to the judgment of investigator
Lab requirements
Blood counts
ANC ≥ 1.5×10^9/L, PLT ≥ 100×10^9/L, Hb ≥ 90g/L (have not accepted blood transfusion or growth factors within 14 days); INR or PT ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN
Kidney function
serum creatinine ≤ 1.5×ULN or estimated glomerular filtration rate (GFR) ≥ 60 mL/min/1.73 m2
Liver function
total bilirubin ≤ 1.5×ULN (total bilirubin <3×ULN for patients with Gilbert syndrome); AST and ALT ≤ 2.5×ULN (AST and ALT ≤ 2.5×ULN for patients with liver metastasis)
Adequate organ function, defined as achieving the following laboratory test results within 7 days before enrollment: ANC≥1.5×10^9/L，PLT≥100×10^9/L，Hb≥90g/L((Have not accepted blood transfusion or growth factors within 14 days)；the international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN; activated partial thromboplastin time(APTT) ≤1.5 × ULN；serum creatinine≤1.5×ULN or estimated glomerular filtration rate(GFR) ≥ 60 mL/min/1.73 m2; total bilirubin≤1.5×ULN（total bilirubin<3×ULN for patients with Gilbert syndrome）; AST and ALT ≤ 2.5×ULN (AST and ALT ≤ 2.5×ULN for patients with liver metastasis);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify